|
10131
|
ACAM2000
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Emergent BioSolutions
|
2003
|
USA
|
Below 12 months of age
|
Single dose
|
Percutaneous
|
NA
|
Recombinant vaccinia viruses derived from replication-competent vaccinia strain
|
Lyophilized
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000
|
NA
|
|
10132
|
JYNNEOS
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Bavarian Nordic
|
NA
|
Denmark
|
18 years and above
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Vaccinia Virus Ankar
|
NA
|
US FDA
|
NA
|
NA
|
Imvamune, Imvanex, MVA-BN
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/jynneos
|
https://www.fda.gov/media/131078/download
|
|
10133
|
Aventis Pasteur Smallpox Vaccine
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
National Institute of Allergy and Infectious Diseases
|
2010
|
USA
|
18 - 32 years
|
NA
|
Percutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00038987
|
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda
|
https://clinicaltrials.gov/ct2/show/NCT00038987
|
|
10134
|
Priorix
|
Measles, Mumps, Rubella, Chickenpox
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
GlaxoSmithKline
|
2019
|
NA
|
11 months - 22 months
|
2 doses 42 days apart
|
Subcutaneous
|
NA
|
Vaccinia Virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00226499
|
https://www.fda.gov/vaccines-blood-biologics/priorix
|
https://clinicaltrials.gov/ct2/show/NCT00226499
|
|
10135
|
Varivax
|
Chickenpox
|
Exanthous
|
Varicella-zoster virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2007
|
USA
|
1 - 12 years
|
2 doses (0.5 ml each) separated by at least 3 months.# First dose: age 12 through 15 months, Second dose: age 4 through 6 years
|
Subcutaneous
|
NA
|
Oka/Merck strain of live-attenuated varicella virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00822237
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
|
|
10136
|
Varivax
|
Chickenpox
|
Exanthous
|
Varicella-zoster virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2007
|
USA
|
12 - 23 months
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Oka/Merck strain of live-attenuated varicella virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
|
|
10137
|
ProQuad
|
Measles, Mumps, Rubella, Varicella
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
1 - 12 years
|
First dose at 12 through 15 months of age and Second dose at 4 through 6 years of age
|
Subcutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00985166
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/proquad
|
|
10214
|
RH-CHIKV EV-CHIKV RHEV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Footpad injection
|
NA
|
R532H-nsP, E515V-nsP2
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10215
|
Delta 5nsP3 DREP-E MVA-CE
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
CHIKV nsP3 envelope and capsid protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10216
|
Ad-CHIKV-SG
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Intranasal
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
Ad-CHIKV-E3/E2/6K, Ad-CHIKV-E3/E2/E1
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10217
|
ChAdOx1-sCHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Intramuscular
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10218
|
VSV G-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Intramuscular
|
NA
|
CHIKV envelope proteins (E1, E2, and E3)
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10219
|
dMAb
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
Intramuscular
|
NA
|
CHIKV envelope proteins (E1, E2, and E3)
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10220
|
pCHIKV-7
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
cDNA of 181/25
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10221
|
CHKV-24
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Intravenous
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10222
|
VRC-CHKVLP059-00-VP
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
National Institute of Health
|
2016
|
USA
|
18 - 50 years
|
10 ug at weeks 0, 4, and 20
|
Intramuscular
|
NA
|
Human HEK293 cells
|
NA
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
NA
|
NCT01489358
|
https://clinicaltrials.gov/ct2/show/NCT01489358
|
NA
|
|
10223
|
USAMRIID
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
1- 2 doses depending on volume and age
|
NA
|
NA
|
NA
|
Formalin inactivated produced in green monkey kidney cells or chick embryonic cells
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10224
|
VLP- NIH
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
3 doses
|
NA
|
NA
|
NA
|
Produced from DNA transfected into human embryonic kidney VRC293
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10225
|
Measles-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV proteins
|
Recombinant measles virus (Schwartz strain) expressing CHIKV VLPs
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10226
|
TSI-GSD-218
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10227
|
CHIKV Delta 5nsP3
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Clinical strain attenuated by targeted mutations in nsP3, 6 K
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10228
|
CHIK001
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
University of Oxford
|
2019
|
NA
|
18 - 50 years
|
NA
|
NA
|
NA
|
Chimpanzee adenovirus expressing CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT03590392
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
https://clinicaltrials.gov/ct2/show/NCT03590392?cond=Chickungunya+Fever&draw=2&rank=29
|
|
10229
|
mRNA-1944
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Phase 1
|
Moderna Inc.
|
2021
|
USA
|
18 - 50 years
|
NA
|
NA
|
NA
|
CHIKV-directed monoclonal antibody
|
NA
|
US FDA
|
Defense Advanced Research Projects Agency
|
NA
|
NA
|
NA
|
NCT03829384
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
https://clinicaltrials.gov/ct2/show/NCT03829384
|
|
10230
|
mRNA-1388
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Phase 1
|
Moderna Inc.
|
2017
|
USA
|
18 - 49 years
|
3 doses on week 0, week 4, post 1 year
|
Intramuscular
|
NA
|
CHIKV structural proteins
|
mRNA based vaccine
|
NA
|
Defense Advanced Research Projects Agency
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
https://www.modernatx.com/pipeline/mrna-1388
|
|
10231
|
VLA1533
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
Valneva
|
2019
|
Austria
|
18 - 39 years
|
3 doses on day 0, 28 and 56
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT03010228
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://clinicaltrials.gov/ct2/show/NCT03010228
|
|
10232
|
VAL-181388
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Phase 1
|
Moderna Inc.
|
2017
|
USA
|
18 - 49 years
|
3 doses on week 0, week 4, post 1 year
|
NA
|
NA
|
NA
|
NA
|
US FDA
|
Defense Advanced Research Projects Agency
|
NA
|
NA
|
NA
|
NCT03325075
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://clinicaltrials.gov/ct2/show/NCT03325075
|
|
10233
|
IRES-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
University of Texas Medical Branch, Takeda Pharmaceutical Company Limited
|
2011
|
USA
|
NA
|
NA
|
Subcutaneous
|
NA
|
La Reunion strain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145802/
|
|
10234
|
EILV/CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
University of Texas Medical Branch
|
2017
|
USA
|
NA
|
NA
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296253/
|
|
10298
|
CHIKV-NoLS
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
N-terminal region of capsid protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10299
|
MV-CHIK
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
0.35 mL single measle vaccine dose, twice injection at day 0 and day 28
|
Intramuscular
|
NA
|
Measles-vectored CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10300
|
EILV/CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
8.8 log10 PFU (C57BL/6) or 8.5 log10 PFU (IFN?/?R–/–mice) of live EILV/CHIKV, single injection
|
Subcutaneous
|
NA
|
EILV cDNA clone containing CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10301
|
CHIK-VLP
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Intramuscular
|
NA
|
C-E proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10302
|
CHIK-VLP
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
NA
|
Subcutaneous
|
NA
|
CHIKV structural proteins introduced into yeast expression system
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10303
|
MV-CHIK
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
Themis Bioscience
|
2021
|
USA
|
21 - 65 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
Walter Reed Army Institute of Research
|
NA
|
NA
|
NA
|
NCT03807843
|
https://clinicaltrials.gov/ct2/show/NCT03807843
|
NA
|
|
10304
|
TSI-GSD-218
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
NA
|
Attenuation by serial, plaque-to-plaque MRC5 cell passages
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10305
|
MV/Schwarz
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10306
|
CHIK-VLP
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 2
|
Emergent BioSolutions
|
2020
|
USA
|
18 - 45 years
|
2 doses on day 0, 29
|
Parenteral or mucosal route
|
Alhydrogel
|
CHIKV structural proteins (C, E3, E2, 6K, E1)
|
NA
|
US FDA
|
National Institute of Health, PaxVax
|
NA
|
NA
|
NA
|
NCT03483961
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://clinicaltrials.gov/ct2/show/NCT03483961
|
|
10307
|
MV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
Institut Pasteur of Shanghai, Themis Bioscience
|
2021
|
NA
|
18 - 55 years
|
3 doses on day 0, 28 and 196
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT02861586
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://clinicaltrials.gov/ct2/show/NCT02861586
|
|
10308
|
MVA-mBN85B
|
Measles
|
Exanthous
|
Morbillivirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 2
|
Bavarian Nordic
|
2012
|
South Africa
|
6 months - 6 years
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Attenuated Modified Vaccinia Virus Ankara, strain encoding hemagglutinin protein, fusion protein and nucleoprotein of measles virus
|
NA
|
NA
|
NA
|
NA
|
Rouvax
|
NA
|
NCT00891007
|
https://clinicaltrials.gov/ct2/show/NCT00891007?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=3
|
NA
|
|
10309
|
MeMuRu-OKA
|
Measles, Mumps, Rubella, Varicella
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
GlaxoSmithKline
|
2016
|
Canada
|
15 months - 6 years
|
NA
|
Subcutaneous
|
NA
|
Jeryl Lynn strain, Schwarz strain, RA 27/3 strain, OKA strain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00352898
|
https://clinicaltrials.gov/ct2/show/NCT00352898
|
https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006065-14/DE
|
|
10372
|
Sf21-VLP (PXVX0317)
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Phase 3
|
Emergent BioSolutions
|
2021
|
NA
|
12 - 65 years
|
NA
|
NA
|
Alhydrogel
|
NA
|
Virus-like particle made using baculovirus and Sf21 insect cells
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT05072080
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
https://clinicaltrials.gov/ct2/show/NCT05072080
|
|
10373
|
PENN CHIKV-2008 (PC-08)
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Phase 3
|
University of Pennsylvania
|
2011
|
USA
|
NA
|
NA
|
NA
|
NA
|
CHIKV envelope proteins (E1, E2, and E3)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019110/
|
|
10374
|
MRVAC
|
Measles, Rubella
|
Exanthous
|
Morbillivirus, Rubella virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Center for Research and Production of Vaccines and Biologicals
|
2018
|
Vietnam
|
1 - 45 years
|
NA
|
Subcutaneous
|
NA
|
Strain AIK-C measles virus clone with Takahashi rubella virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT03713359
|
https://clinicaltrials.gov/ct2/show/NCT03713359?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=54
|
NA
|
|
10385
|
DeltaC-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
Capsid deletion
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10386
|
Stop CHIKV SuperStop CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Footpad injection
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10387
|
DRDE-06
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
3 doses
|
NA
|
NA
|
NA
|
Formalin inactivated produced in vero cells
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10388
|
CHIK-E1/E2
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
3 doses
|
NA
|
NA
|
E1/E2
|
Recombinant E1/E2 produced in E. coli
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10389
|
CHIK-E2
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
2 doses
|
NA
|
NA
|
E1
|
Recombinant E2 produced in E. coli
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10390
|
VLP-CHIKV-S27
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
2 doses
|
NA
|
NA
|
CHIKV proteins
|
Baculovirus-vectored CHIKV VLPs formulated with adjuvant
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10391
|
Chimeric alphavirus
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
Recombinant alphavirus (EEEV, VEEV, SINV) with CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10392
|
CHIKV/IRES
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10393
|
VSV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10394
|
CAdVax-CHIK
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
GenPhar Inc.
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
Produced in HEK293 packaging cell line
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
https://www.sciencedirect.com/science/article/pii/S0264410X16300731
|
|
10395
|
MVA-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10396
|
pMCE321
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
Intramuscular
|
NA
|
Sequence of E3, E2, and E1 genes under a CMV promoter
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10397
|
iDNA
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
Intramuscular
|
NA
|
CHIKV strain 181/25
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10398
|
DREP-Env
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
Intradermal
|
NA
|
CHIKV replicon (nsP1 to nsP4) and CHIKV envelope proteins (E1, E2, and E3)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10399
|
LR-E2-E79 K
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Clinical strain LR attenuated by mutations in heparin sulfate binding domains
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10400
|
CHIKV TM17-2
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Clinical strain attenuated by mutations in E2 transmembrane domain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10401
|
CHIKV/IRES
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10402
|
VSVdelG-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Glycoprotein-deficient VSV encoding CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10403
|
VEE/CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Chimera consisting of VEEV nsP and CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
VEE/IRES-C/CHIKV
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10404
|
EILV/CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Eilat virus nonstructural and CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10405
|
CAdVax-CHIK
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Replication-deficient Ad5 encoding CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10406
|
MVA-6KE1E3E2
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
MVA encoding CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10407
|
MVA-E2E3
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV envelope protein (E2, E3)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10408
|
MVA-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
Intraperitoneal
|
NA
|
CHIKV structural proteins (C, E3, E2, 6K, E1) into MVA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10409
|
UV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by UV-irradiation
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10410
|
BEI-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by binary ethyleneimine
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10411
|
Formalin-inactivated CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by formalin
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10412
|
Tween/Ether-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by Tween 80 and ether
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10413
|
rCHIKVE1/E2
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Recombinant E1 and E2 proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10414
|
rE2p
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Recombinant E2 protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10415
|
p181/25-7
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV strain 181/25
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10416
|
CVM1-IgG
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
E2-reactive monoclonal antibody
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10417
|
pVax1-MCE321
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV envelope proteins (E1, E2, and E3)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10418
|
DREP-Env
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
Intradermal
|
NA
|
DNA replicon encoding nsP and E1, E2, E3
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|